One study by Mitchell et al. [89] demonstrated that ponatinib-resistant CML cells can develop BCR-ABL-independent resistance through alternative activation of the mTOR pathway. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.